The Patent Finder
AO

Aurigene Oncology Limited

First filing 2014
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Aurigene Discovery Technologies Limited (to 2022)

47 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Oct 2032. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Oct 2032
Next term end
21
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Dual Inhibitors of TIM-3 and PD-1 Pathways US 11,497,734
Cited by 21 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2038.
Ends Dec 2038 · High confidence
Also notable
Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors US 9,732,095
Cited by 45 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Ends Jan 2035 · High confidence
Also notable
1,2,4-Oxadiazole Derivatives as Immunomodulators US 10,590,093
Cited by 22 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Ends Sep 2034 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 20, 2026
    The maintenance fee for Crystalline Forms of 3-Substituted 1,2,4- Oxadiazole (US 11,680,051) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 1 fee due Jan 4, 2027
    The maintenance fee for Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors (US 11,691,987) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 1 fee due Feb 27, 2027
    The maintenance fee for Protein Kinase Inhibitors (US 10,391,082) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
  • 2 fees due Jul 9, 2027
  • 2 fees due Sep 17, 2027
  • 2 fees due Nov 5 to 14, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 22, 2026
  • 1 term has ended since Aug 22, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,447,091Protein Kinase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,391,082Protein Kinase Inhibitors
In force
 · Low confidence
In forceLow confidence
US 9,630,932Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,937,155Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 10,080,740Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,147,801Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
In force
 · Low confidence
In forceLow confidence
US 12,290,507Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 9,771,3381,2,4-Oxadiazole Derivatives as Immunomodulators
In force
 · High confidence
In forceHigh confidence
US 10,173,9891,2,4-Oxadiazole Derivatives as Immunomodulators
In force
 · High confidence
In forceHigh confidence
US 10,590,0931,2,4-Oxadiazole Derivatives as Immunomodulators
In force
 · High confidence
In forceHigh confidence
10 of 47 patents shown.
Pro members see all 47.
Pro members: see all 47 patents
Also on record, not counted in the 47: 1 patent in force now held by others · 5 patents ended · 32 applications pending · 14 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited